40.6K
Downloads
118
Episodes
Equity.Guru's Chris Parry and his expert journalism team talk to business leaders, executives and investors about opportunities in North America and beyond.
Episodes
Friday Feb 15, 2019
Friday Feb 15, 2019
Titan Pharmaceuticals (TTNP.Q) is an American pharmaceutical company based out of San Francisco, California. The company has recently relaunched Probuphine, its six-month treatment for Opioid Use Disorder (OUD).
The company reacquired the rights to Probuphine from Braeburn Pharmaceuticals. Since the June 2018 relaunch, sales of Probuphine have increased over 20% and the company has doubled its staff.
The Center for Disease Control says 130 Americans die every day from an opioid overdose. We spoke to Kate DeVarney, Titan's CSO and executive vice president , about the life-changing effect Probuphine can have on someone struggling with opioid addiction and the company's pilot program for treating OUD within Nevada's prison population.
Listen in!
--Ethan Reyes
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.